Galon J, Pags F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S , Sinicrope FA , Trinchieri G, Gajewski TF, Ascierto PA, Fox BA
quick to administer Slower absorption may provide a prolonged effect Suitable for self-injection under a providers guidance (if permitted) Considerations: Localized soreness possible at injection site Slightly lower bioavailability than IV, but still effective Who It's For: Individuals seeking consistent access to glutathione without the time commitment or discomfort of IV therapy
2011 DOI: 10.1152/japplphysiol.00945.2010 PMID: 21030672 Read on PubMed Neural Regeneration Research Pentadecapeptide BPC 157 and the central nervous system Vukojevic J, Milavi M, Perovi D, et al
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress
